Maze Therapeutics Announces $190 Million Financing ...
Maze Therapeutics secures $190M financing to advance nine precision medicine programs and its Compass platform for genetically defined diseases. MZE001 for Pompe disease expected to enter clinical trials in H1 2022. Andy Tran joins board. Funding supports rare and common disease treatments, including Pompe, chronic kidney disease, and ALS.
Reference News
Maze Therapeutics Announces $190 Million Financing ...
Maze Therapeutics secures $190M financing to advance nine precision medicine programs and its Compass platform for genetically defined diseases. MZE001 for Pompe disease expected to enter clinical trials in H1 2022. Andy Tran joins board. Funding supports rare and common disease treatments, including Pompe, chronic kidney disease, and ALS.